News & Videos - CARMAT - English

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to initiate the second cohort of its Early Feasibility Study (EFS) with Aeson® artificial heart in the United States....

Regulatory News: CARMAT (Paris:ALCAR): Videoconference in English and French this evening. To join, please register by clicking on one of the following links: Videoconference in French at 6:00 pm CEST - Videoconference in English at 8:00 pm CEST CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces the publication of the results of the initial clinical experience with Aeson® in cardiogenic shock patients previously on temporary extracorporeal life support 2 , in the JACC: Heart Failure . Study...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), will publish a business update and host a videoconference on Wednesday, April 9, 2025 after the market closes. The videoconference will be held in French at 6:00 pm (CEST) and then in English at 8:00 pm (CEST). The...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), announces the implementation of a flexible equity financing line with IRIS Capital Investment (“ IRIS ”), for a maximum of 9,000,000 shares (i.e., approximately 15% of its current share capital), over a 24-month period....

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces the publication in The Journal of Heart and Lung Transplantation , of an article on the performance of Aeson® total artificial heart in treating heart failure patients with pulmonary hypertension. Study...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces that it has passed the milestone of 100 implants of its Aeson® artificial heart. Symbolic milestone of 100 Aeson® artificial heart implants passed The 99th and 100th implants were successfully performed on...

Regulatory News: NOT FOR DIRECT OR INDIRECT DISTRIBUTION IN THE UNITED STATES OF AMERICA, SOUTH AFRICA, CANADA, AUSTRALIA OR JAPAN CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces the completion of its global offering for a total gross amount of €9.7 million,...

Regulatory News: NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces the launch of a global offering of approximately €10 million, through the issuance of new...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announces its indicative financial calendar for 2025. This preliminary agenda may be modified. Each publication will be released before market opening. Event Date 2024 Full-Year Results Tuesday, April 29, 2025...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), today announced its participation in the following scientific and investor conferences during the 1 st half of 2025: Scientific Conferences 35 th Journées Européennes de la SFC (French Society of Cardiology) January 15 to 17,...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), announces its 2024 annual sales 2 and provides an update on its development outlook. Stéphane Piat, Chief Executive Officer of CARMAT, stated: “With 42 implants of our Aeson® artificial heart and €7 million in sales, i.e....

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), announced today that it has bought-back 2 million shares from Matra-Défense (Airbus group) (“ Airbus ”), for a symbolic sum of one euro, which will be used to repay the Company's financial debt, via their use in the...

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125445962/en/ (Photo: Business Wire) CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), announces the success of its first "Aeson® European User Meeting", held on 21...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “ Company ” or “ CARMAT ”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe. Growing adoption of Aeson® as a bridge-to-transplant solution in Europe By the end of October 2024, 30 patients had successfully...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General Meeting (AGM) held on May 11, 2023 was able to validly deliberate, the required quorum having been reached. The AGM adopted all proposed resolutions, with the exception of the 28 th resolution which was...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announces that it has obtained non-dilutive financing of €13.2 million as part of the “France 2030” plan, and the extension of its cash runway through to mid-October 2023. Non-dilutive financing of €13.2 million to increase and...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from advanced biventricular heart failure, today announced the publication of the Company’s Universal registration document for the year ended December 31, 2022. The document, filed with the French stock-market authority ( Autorité des Marchés Financiers...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announced that the first U.S. clinical experience with Aeson® has been published in the Annals of Thoracic Surgery Short Reports, the journal of the U.S. Society of Thoracic Surgeons. The article, entitled The First Autoregulated...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announces its annual results for the year ending December 31, 2022 1 and confirms its 2023 objectives. Stéphane Piat, Chief Executive Officer of CARMAT, said: “ Thanks to the efforts of the whole CARMAT team, we have achieved our main objective for...